APRE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

APRE ▼ -6.84% at T+20d

LONG call ✗ call lost -6.84% · α vs SPY -11.75% · entry $0.9070 → $0.8450

Next anchor: T+60d in 4w

Last close $0.6860 (close Jun 12) · -24.37% from $0.9070 entry

Entry anchored
Apr 21, 10:12 AM ET
via Databento tick

T+1d

+4.74%

call +4.74% · α +3.72%

$0.9500

settled 8w ago

T+5d

-7.72%

call -7.72% · α -8.80%

$0.8370

settled 7w ago

T+20d

-6.84%

call -6.84% · α -11.75%

$0.8450

settled 27d ago

T+60d

—

call — · α —

—

in 4w

Price Chart

Loading chart...

Executive Summary

Aprea Therapeutics announced that early results from the first-in-human Phase 1 trial of its WEE1 inhibitor APR-1051 will be presented at the 2026 ASCO Annual Meeting. This marks a clinical milestone for the company's lead oncology program in biomarker-defined solid tumors.

Actionable Insight

The ASCO abstract presentation is a near-term catalyst likely to drive trading activity. Traders should monitor for data disclosures on efficacy and safety from the first-in-human study, which could revalue the pipeline despite the company's small market cap.

Key Facts

APRE announced acceptance of an abstract for APR-1051 Phase 1 trial results at ASCO 2026
Presentation scheduled for May 30, 2026, during Developmental Therapeutics session
APR-1051 is an oral WEE1 inhibitor in development for advanced solid tumors
Trial identifier: NCT06260514
Company has multiple clinical-stage oncology programs, including ATRN-119

Financial Impact

Non-financial clinical milestone with potential to increase investor sentiment and valuation interest

market sentimentpipeline valueinvestor confidence

Risk Factors

Early-phase data may show limited efficacy or safety concerns
Low market cap and limited liquidity increase volatility risk
Forward-looking statements subject to clinical development risks

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3278152

9 reports for APRE

T+1T+5T+20T+60

80% Hit rate 4 of 5 directional calls best @ T+5▲ +8.21%Mar 17, 2026

Filters

Reports for APRE — sortable, filterable
	Type				Now
May 13, 2026 4w ago	8-K BULLISH ★ 7/10	$0.8800 $0.8000	▼ −9.09%	▼ −7.93%	$0.6860 (−22.05%)
May 13, 2026 4w ago	Press Release NEUTRAL ★ 5/10	$0.8800 $0.8000	▼ −9.09%	▼ −7.93%	$0.6860 (−22.05%)
Apr 30, 2026 6w ago	DEFA14A BEARISH ★ 7/10	$0.8000 $0.8810	▼ −10.13%	▼ −8.40%	$0.6860 (+14.25%)
Apr 22, 2026 7w ago	S-3 BEARISH ★ 7/10	$0.8840 $0.8190	▲ +7.35%	▲ +8.83%	$0.6860 (+22.40%)
Apr 21, 2026 7w ago	Press Release BULLISH ★ 7/10	$0.9070 $0.8370	▼ −7.72%	▼ −8.80%	$0.6860 (−24.37%)
Mar 31, 2026 10w ago	Insider Cluster BULLISH ★ 6/10	$0.7630 $0.7020	▼ −7.99%	▼ −11.94%	$0.6860 (−10.09%)
Mar 20, 2026 12w ago	EFFECT NEUTRAL ★ 4/10	$0.7620 $0.6830	▼ −10.37%	▼ −8.22%	$0.6860 (−9.97%)
Mar 17, 2026 12w ago	S-3/A BEARISH ★ 4/10	$0.7310 $0.6710	▲ +8.21%	▲ +7.49%	$0.6860 (+6.16%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$0.7560 $0.6820	▼ −9.79%	▼ −7.75%	$0.6860 (−9.26%)

US Market Status

Market Closed — Opens in 5h 6m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access